Micronbrane

Micronbrane Medical is committed to advancing metagenomic Next-Generation Sequencing (mNGS) to deliver fast and precise identification of both known and novel microorganisms. While mNGS holds immense potential for infectious disease diagnostics, its accuracy depends on minimising contamination from the host, the workflow, and the analysis process.

Micronbrane’s mission is to overcome the technical and cost barriers associated with mNGS, making it accessible and sustainable for global health applications. To achieve this, the company has developed Pathogen Real-Time Identification by Sequencing (PaRTI-Seq), a complete assay, and the bioinformatic web application PaRTI-Cular. These innovations enable mNGS to be used easily and cost-effectively, positioning it as a first-line solution for diagnosing and treating infectious diseases.

Contact our Micronbrane specialists to learn more about the portfolio.